Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitis.
Pediatr Dermatol
; 40(1): 132-134, 2023 Jan.
Article
em En
| MEDLINE
| ID: mdl-36403606
ABSTRACT
In our cohort study, we sought to describe the utilization patterns of systemic immunomodulators in children with atopic dermatitis (AD) and how utilization changed after approval of dupilumab, the first systemic drug approved for the treatment of AD. Using US nationwide claims data, we identified children with AD who initiated a systemic therapy (dupilumab, cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil) from March 2015 to February 2021 and used Sankey plots to describe patterns of starting, switching, and discontinuing these drugs. Dupilumab use among children increased from 19.4% before approval in children to 88.3% after approval in 2019-20. Adherence to dupilumab may suggest better tolerance and improved outcomes in children with AD.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dermatite Atópica
Tipo de estudo:
Observational_studies
Limite:
Child
/
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article